Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Catheters Market
The global catheters market is projected to grow from USD 10.0 billion in 2025 to USD 18.8 billion by 2035, reflecting a CAGR of 6.5%. This expansion is driven by rising prevalence of chronic diseases, increasing adoption of minimally invasive procedures, and growing demand for advanced catheter technologies across hospital, specialty center, and ambulatory surgical center settings.
Market size
Growth trajectory through 2035
Catheters Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Innovation in antimicrobial coatings
- Companies are investing in next-generation coatings to reduce catheter-associated infections (CAUTIs), with products like Bard’s BARDEX I.C. Foley catheters gaining traction.
-
Development 02 Expansion into home healthcare
- Growing focus on portable and user-friendly catheter systems to support home dialysis and urinary drainage management.
-
Development 03 Partnerships with ASCs
- Collaborations to standardize catheter use in outpatient procedures, driving procedural volumes and market penetration.
-
Development 04 Regulatory approvals
- Faster approvals for neurovascular and biliary catheters in key markets, supported by favorable reimbursement policies.
Emerging opportunities added
- Emerging markets expansion Growth in healthcare infrastructure and rising disposable incomes in Asia-Pacific, Latin America, and Middle East & Africa present untapped potential for catheter adoption.
- Home healthcare and telemedicine integration Increasing preference for home-based dialysis and urinary catheter management creates demand for user-friendly, portable catheter systems.
- R&D in advanced materials and coatings Development of next-generation antimicrobial and biocompatible coatings can reduce infection risks and extend catheter longevity.
- Partnerships with ambulatory surgical centers (ASCs) Collaborations with ASCs to standardize catheter use in outpatient procedures can drive procedural volumes and market penetration.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 33.5% share
- Leading region
- North America
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory and approval hurdles
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Innovation in antimicrobial coatings: Companies are investing in next-generation coatings to reduce catheter-associated infections (CAUTIs), with products like Bard’s BARDEX I.C. Foley catheters gaining traction
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 120-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Catheters Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of Cardiovascular catheters (angiography, IVUS/OCT, guiding and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Diagnostic imaging, embolization, thrombectomy applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Cardinal Health, Owens & Minor, Henry Schein Inc and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Aging population and rising chronic disease prevalence) and top restraints (led by Regulatory and approval hurdles), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Aging population and rising chronic disease prevalence Increasing incidence of cardiovascular, urological, and neurovascular disorders drives demand for catheter-based interventions, particularly in elderly populations.
- Growth of minimally invasive procedures Advances in catheter technologies enable precise, less invasive treatments, reducing recovery times and improving patient outcomes.
- Expansion of home healthcare and ambulatory settings Shift toward outpatient and home-based care increases reliance on catheters for chronic disease management, including dialysis and urinary drainage.
- Technological innovation in catheter design Development of antimicrobial coatings, power-injectable systems, and workflow-integrated catheters enhances safety, efficacy, and procedural efficiency.
- Favorable reimbursement policies Supportive healthcare policies and reimbursement frameworks for catheter-based interventions stimulate market adoption, particularly in neurovascular and dialysis segments.
Restraints
Holding it back
- Regulatory and approval hurdles Extended timelines for product approvals and compliance with stringent clinical protocols delay market entry for innovative catheter designs.
- Supply chain disruptions Component shortages and logistical challenges, particularly for specialized materials, impact production and pricing stability.
- High cost of advanced catheters Premium pricing for antimicrobial, power-injectable, and multi-lumen catheters limits adoption in price-sensitive markets and restricts access in developing regions.
- Risk of catheter-associated infections (CAUTIs) Nosocomial infections linked to urinary and central venous catheters pose clinical and financial burdens, necessitating stricter infection control measures.
- Pricing pressure from tenders and procurement models Value-based procurement and tender processes constrain price realization, particularly in hospital-centric markets.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Aging population and rising chronic disease prevalence | +2.9% | Global | 2025–2035 |
| Growth of minimally invasive procedures | +1.8% | Global | 2025–2035 |
| Expansion of home healthcare and ambulatory settings | +1.4% | Global | 2025–2035 |
| Technological innovation in catheter design | +1.0% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory and approval hurdles | −1.2% | Global | 2025–2029 |
| Supply chain disruptions | −0.8% | Global | 2025–2029 |
| High cost of advanced catheters | −0.6% | Global | 2025–2029 |
The catheters market is segmented by product type, application, end-user, and region.
Revenue share by type · 2025 base year
% OF $10.00 BN CATHETERS MARKET · 8 TYPES COVERED
Each slice = that type's share of the total $10.00 Bn Catheters Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Cardiovascular catheters (angiography
-
IVUS/OCT
-
guiding
-
urological catheters (urinary
-
indwelling/Foley
-
intermittent
-
external
-
dialysis catheters (hemodialysis
By application
-
Diagnostic imaging
-
embolization
-
thrombectomy
-
targeted drug delivery
-
urinary drainage
-
incontinence management
-
surgical drainage
-
hemodialysis access
By end-user industry
-
Hospitals
-
specialty centers
-
ambulatory surgical centers (ASCs
By capacity
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~37.3% in 2025. Dominates the market due to high healthcare expenditure, advanced medical infrastructure, and strong presence of key players. The region benefits from high adoption of advanced catheter technologies …
Per-region detail
-
North America
Dominates the market due to high healthcare expenditure, advanced medical infrastructure, and strong presence of key players. The region benefits from high adoption of advanced catheter technologies and supportive reimbursement policies
-
Europe
Holds a significant share, driven by aging population, increasing prevalence of chronic diseases, and robust healthcare systems. Germany, the UK, and France are major contributors to regional growth
-
Asia-Pacific
The fastest-growing region, fueled by expanding healthcare access, rising disposable incomes, and increasing incidence of cardiovascular and urological disorders. China, Japan, and India are key markets
-
Latin America
Growth is supported by improving healthcare infrastructure and rising demand for dialysis and urinary catheters. Brazil and Mexico are primary contributors
-
Middle East & Africa
Emerging market potential driven by increasing healthcare investments and rising prevalence of chronic diseases. Saudi Arabia, UAE, and South Africa are key focus areas
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The catheters market is moderately concentrated, with leading players maintaining competitive edges through broad portfolios, clinical evidence, and established hospital contracting channels. Key companies include Pfizer, Johnson & Johnson, Merck, Novartis, Roche, AbbVie, Eli Lilly, AstraZeneca, GSK, and GlaxoSmithKline.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Cardinal Health
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Owens & Minor
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Henry Schein Inc
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
3M Health Care
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Kimberly-Clark Health Care
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Molnlycke Health Care
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Smith & Nephew plc
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
ConvaTec Group plc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Catheters Market in 2025?
The Catheters Market is estimated at approximately $10.00 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 6.50% CAGR from 2025 to 2035, reaching $18.77 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 37.3% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Cardiovascular catheters (angiography leads the type segmentation with an estimated 33.5% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Cardinal Health, Owens & Minor, Henry Schein Inc, 3M Health Care, Kimberly-Clark Health Care, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Aging population and rising chronic disease prevalence. Increasing incidence of cardiovascular, urological, and neurovascular disorders drives demand for catheter-based interventions, particularly in elderly populations.
-
What are the main restraints?
The primary restraint is Regulatory and approval hurdles. Extended timelines for product approvals and compliance with stringent clinical protocols delay market entry for innovative catheter designs.
-
What are the most recent developments?
Recent notable events include: : Innovation in antimicrobial coatings: Companies are investing in next-generation coatings to reduce catheter-associated infections (CAUTIs), with products like Bard’s BARDEX I.C. Foley catheters gaining traction; : Expansion into home healthcare: Growing focus on portable and user-friendly catheter systems to support home dialysis and urinary drainage management; : Partnerships with ASCs: Collaborations to standardize catheter use in outpatient procedures, driving procedural volumes and market penetration. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Catheters Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.